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j ourna l homepage: http : / /www. journa ls .e lsev ie r .com/bba-c l i n i ca l /EditorialLaunch of BBA Clinical: Translating molecular insights to clinical researchBiochimica et Biophysica Acta (BBA) began publication in 1947. It
was the ﬁrst international journal dedicated to the publication of new
ﬁndings from the emerging and synergistic ﬁelds of biochemistry
and biophysics. Since that time, the titles within the BBA series have
expanded to meet the needs of scientists focused on understanding
the physics, molecular mechanisms, and biochemical underpinnings in
diverse ﬁelds, including bioenergetics, proteomics, and lipid biology.
Today, we announce the newest title in the BBA collection, BBA
Clinical, which is dedicated solely to human research studies. BBA Clinical
will provide an important new forum for clinical researchers who use
observational and clinical trial studies to understand the molecular
and biochemical processes involved in human disease. The mission of
BBA Clinical is to meet the needs of these researchers, as well as to pro-
vide a new resource for investigators who target biochemical pathways
and processes in clinical trials and observational studies.
Our new BBA title is designed to build upon the history and promi-
nence of this journal. Articles published in BBA Clinical will provide
new insights concerning the biochemical mechanisms related to the di-
agnosis, progression, and treatment of a wide range of human diseases.
Studies in the areas of aging, cardiovascular disease, hepatic disease,
kidney disease, Alzheimer's disease, Parkinson's disease, immune disor-
ders, and cancer are particularly encouraged. Studies that incorporate
cutting-edge imaging studies or other mechanistic approaches in clini-
cal research are also invited. BBA Clinical has several key features to
help ensure the impact of its content. Among these are timely and
constructive manuscript evaluation by highly qualiﬁed reviewers, and2214-6474/$ – see front matter © 2013 Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.bbacli.2013.10.001an Editorial Board that includes Chief Editors for Clinical Research
(Dr. Russell Swerdlow) and for Statistics (Dr. Ralph D'Agostino Jr.).
We live in the most exciting time in the history of clinical research.
The scope and novelty of clinical research today,with new technological
advances and intradisciplinary studies of humanphysiology andpathol-
ogy, are unprecedented. Such efforts have provided numerous break-
throughs in the detection, management, treatment, and, most
importantly, the prevention of many human diseases; and they have
initiated starting points for the future of clinical research. BBA Clinical
is intended to provide a new platform for the dissemination and fur-
therance of the novel and important clinical research that arises from
each of these advances. Importantly, BBA Clinical will provide not just a
useful forum for clinical research today: It is designed to be a prominent
contributor to the larger overall body of clinical advancements far into
the future, much as the original BBA journal has successfully done in
the ﬁelds of biochemistry and biophysics over the past sixty-six years.
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